Status: Recruiting
A Study of GC203 TIL in PDCA (RJ)
This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Participants needed: 10
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Shanghai Juncell TherapeuticsUpdated: Dec 23, 2025Locations: 1
Eligibility criteria
have done the tumor resection for gene-edited GC203 TIL production and successfu... [+6]
with other malignant tumors,except for the malignancies that have been cured, ha... [+18]